Showing 1021-1030 of 1614 results for "".
- Glaukos Enters into a Collaboration and Marketing Agreement with Radius XRhttps://modernod.com/news/glaukos-enters-into-a-collaboration-and-marketing-agreement-with-radius-xr/2481728/Glaukos announced that it has entered into a collaboration and marketing agreement with Radius XR, whereby Glaukos will become the exclusive sales agent to market, promote, and solicit orders for the Radius XR wearable patient engagement and diagnostic system within the United States. Radius
- Market Scope: Improved Vitrectomy Machine Features Expected to Expand Retinal Treatmentshttps://modernod.com/news/market-scope-improved-vitrectomy-machine-features-expected-to-expand-retinal-treatments/2481617/Advancements in vitrectomy machine technology are expected to improve safety and efficacy and enable surgeons to reach a larger population of patients with retinal disease over the next 5 years, according to a Market Scope report. These advancements include small-incision vitrectomy, subretinal t
- Novaliq Plans to File a Marketing Authorization Application for CyclASol in the EU for Dry Eye Diseasehttps://modernod.com/news/novaliq-plans-to-file-a-markting-authorization-application-for-cyclasol-in-the-eu-for-the-treatment-of-dry-eye-disease-in-july-2023/2481396/Novaliq announced its plans for filing a marketing authorization application (MAA) CyclASol (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED), in the European Union. The Committee for Medicinal Products for H
- Eyenuk Secures the First European Union MDR Certification for Autonomous AI Detection of DR, AMD, and Glaucomahttps://modernod.com/news/eyenuk-secures-the-first-european-union-mdr-certification-for-autonomous-ai-detection-of-diabetic-retinopathy-amd-and-glaucoma/2481377/Eyenuk has been approved to market its EyeArt AI eye screening system in the European Union for the new uses of detecting age-related macular degeneration (AMD) and glaucomatous optic nerve damage. The EyeArt AI system (version 3.0) has been granted a new European Commiss
- Outlook Therapeutics Announces Validation of Marketing Authorization Application by the EMA for ONS-5010 for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-validation-of-marketing-authorization-application-by-the-european-medicines-agency-for-ons-5010-as-a-treatment-for-wet-amd/2481308/Outlook Therapeutics announced the validation of its marketing authorization application (MAA) by the European Medicines Agency (EMA) for ONS-5010 / Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degener
- Lucentis Biosimilar Ranivisio Receives Marketing Authorization from European Commissionhttps://modernod.com/news/european-commission-grants-marketing-authorization-for-ranivisio-for-amd/2481057/Teva Pharmaceuticals announced that it has received marketing authorization from the European Commission for Ranivisio (ranibizumab), a biosimilar of Lucentis. The authorization includes all five indications for which Lucentis is authorized in adults.
- LKC Appoints New Members of Sales and Marketing Leadershiphttps://modernod.com/news/lkc-appoints-new-members-of-sales-and-marketing-leadership/2480999/LKC Technologies, a provider of electroretinography devices, announced the hiring of two industry professionals to lead their strategic efforts to expand its foothold in the US optometric market. Gary VanMatre was appointed Vice President, US Sales, and will lead a geographica
- NovaBay Pharmaceuticals Targets New Market with Antimicrobial Avenova Lid and Lash Spray for Lash Extensionshttps://modernod.com/news/novabay-pharmaceuticals-targets-new-market-with-antimicrobial-avenova-lid-and-lash-spray-for-lash-extensions/2480997/NovaBay Pharmaceuticals announced the launch of a new marketing campaign targeting the large and growing number of women who wear eyelash extensions. This campaign represents the first step in a larger growth initiative to introduce the Avenova brand to an new group of consumers.</
- Global Data: Increasing Cataract Surgical Rates Will Drive Artificial Lenses Market to Reach $4.7 Billion by 2030https://modernod.com/news/global-data-increasing-cataract-surgical-rates-will-drive-artificial-lenses-market-to-reach-47-billion-by-2030/2480953/The global market for IOLs is forecast by GlobalData to steadily grow from $4.3 billion in 2021 to $4.7 billion by the end of the decade. The data and analytics company notes that this growth is primarily driven by the growing capacity of many hospitals and clinics across all regions to perform m
- SIFI Announces EMA Validation of its Marketing Authorization Application for Akantior for the Treatment of Acanthamoeba Keratitishttps://modernod.com/news/sifi-announces-ema-validation-of-its-marketing-authorization-application-for-akantior-for-the-treatment-of-acanthamoeba-keratitis/2480899/SIFI announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for Akantior (polihexanide) for the treatment of acanthamoeba keratitis (AK). Today's announcement follows the company’s announcement in October 2